NO20003848D0 - FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien - Google Patents

FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien

Info

Publication number
NO20003848D0
NO20003848D0 NO20003848A NO20003848A NO20003848D0 NO 20003848 D0 NO20003848 D0 NO 20003848D0 NO 20003848 A NO20003848 A NO 20003848A NO 20003848 A NO20003848 A NO 20003848A NO 20003848 D0 NO20003848 D0 NO 20003848D0
Authority
NO
Norway
Prior art keywords
lymphotoxin
follicular lymphoma
pathway inhibitors
treating follicular
treating
Prior art date
Application number
NO20003848A
Other languages
English (en)
Other versions
NO328116B1 (no
NO20003848L (no
Inventor
Jeffrey Browning
Jeanette Thorbecke
Vincent Tsiagbe
Original Assignee
Biogen Inc
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Univ New York filed Critical Biogen Inc
Publication of NO20003848D0 publication Critical patent/NO20003848D0/no
Publication of NO20003848L publication Critical patent/NO20003848L/no
Publication of NO328116B1 publication Critical patent/NO328116B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20003848A 1998-01-30 2000-07-27 Anvendelse av inhibitorer for lymfotoksin-beta for fremstilling av farmasoytiske sammensetninger mot folikkulaert lymfom. NO328116B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7311298P 1998-01-30 1998-01-30
US7341098P 1998-02-02 1998-02-02
PCT/US1999/001928 WO1999038525A1 (en) 1998-01-30 1999-01-29 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway

Publications (3)

Publication Number Publication Date
NO20003848D0 true NO20003848D0 (no) 2000-07-27
NO20003848L NO20003848L (no) 2000-10-02
NO328116B1 NO328116B1 (no) 2009-12-14

Family

ID=26754147

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003848A NO328116B1 (no) 1998-01-30 2000-07-27 Anvendelse av inhibitorer for lymfotoksin-beta for fremstilling av farmasoytiske sammensetninger mot folikkulaert lymfom.

Country Status (24)

Country Link
EP (1) EP1051187B9 (no)
JP (2) JP4713733B2 (no)
KR (1) KR100622960B1 (no)
CN (1) CN1287853C (no)
AT (1) ATE253930T1 (no)
AU (1) AU752710B2 (no)
BR (1) BR9908214A (no)
CA (1) CA2319698A1 (no)
CZ (1) CZ301026B6 (no)
DE (1) DE69912743T2 (no)
DK (1) DK1051187T3 (no)
EA (1) EA003862B1 (no)
EE (1) EE05235B1 (no)
ES (1) ES2211035T3 (no)
HU (1) HU226044B1 (no)
IL (2) IL137489A0 (no)
IS (1) IS2254B (no)
NO (1) NO328116B1 (no)
NZ (1) NZ506529A (no)
PL (1) PL203279B1 (no)
PT (1) PT1051187E (no)
SK (1) SK285725B6 (no)
TR (2) TR200101693T2 (no)
WO (1) WO1999038525A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL353057A1 (en) * 1999-06-28 2003-10-06 Basf Aktiengesellschaft Method for preventing tumoral growth
US7148061B2 (en) 2000-02-11 2006-12-12 The United States Of America As Represented By The Department Of Health And Human Services Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
PL366307A1 (en) 2000-10-13 2005-01-24 Biogen, Inc. Humanized anti-lt-beta-r antibodies
CN101259120B (zh) 2002-03-04 2012-07-04 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
CA2491480A1 (en) 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
WO2004016317A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
NZ538509A (en) * 2002-08-14 2007-11-30 Univ Erasmus Medical Ct Use of murine genomic regions identified to be involved in tumor development for the development of anit-cancer drugs and diagnosis of cancer
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
CN101600450A (zh) 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use

Also Published As

Publication number Publication date
PL342063A1 (en) 2001-05-21
EA003862B1 (ru) 2003-10-30
DE69912743D1 (de) 2003-12-18
TR200101693T2 (tr) 2002-06-21
CN1287853C (zh) 2006-12-06
IL137489A0 (en) 2001-07-24
AU2348899A (en) 1999-08-16
CZ301026B6 (cs) 2009-10-14
EA200000798A1 (ru) 2001-02-26
DE69912743T2 (de) 2004-09-23
WO1999038525A1 (en) 1999-08-05
JP2010235621A (ja) 2010-10-21
EE05235B1 (et) 2009-12-15
AU752710B2 (en) 2002-09-26
EP1051187B9 (en) 2004-08-11
HUP0102363A3 (en) 2004-04-28
PL203279B1 (pl) 2009-09-30
EP1051187A1 (en) 2000-11-15
ES2211035T3 (es) 2004-07-01
NO328116B1 (no) 2009-12-14
SK11302000A3 (sk) 2001-01-18
IL137489A (en) 2010-05-31
KR20010040497A (ko) 2001-05-15
ATE253930T1 (de) 2003-11-15
CN1289252A (zh) 2001-03-28
HU226044B1 (en) 2008-03-28
JP4713733B2 (ja) 2011-06-29
EE200000446A (et) 2001-08-15
HK1029944A1 (en) 2001-04-20
HUP0102363A2 (hu) 2001-10-28
DK1051187T3 (da) 2004-03-08
BR9908214A (pt) 2000-11-28
SK285725B6 (sk) 2007-07-06
CA2319698A1 (en) 1999-08-05
IS5570A (is) 2000-07-21
TR200002203T2 (tr) 2000-12-21
EP1051187B1 (en) 2003-11-12
NZ506529A (en) 2002-12-20
NO20003848L (no) 2000-10-02
PT1051187E (pt) 2004-03-31
JP2002501902A (ja) 2002-01-22
CZ20002751A3 (cs) 2000-12-13
IS2254B (is) 2007-06-15
KR100622960B1 (ko) 2006-09-12

Similar Documents

Publication Publication Date Title
MY151032A (en) Treatment of tnf? related disorders
ES2153337T1 (es) Inhibidores de raf-quinasa.
MY121548A (en) Compounds and methods for the treatment of cancer
NZ506329A (en) Inhibitors of phospholipase enzymes
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
AP9901478A0 (en) Compounds for the treatment of ischemia.
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
TR200003206T2 (tr) İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları.
ID25853A (id) Penghambat saluran kalium
NO20003848L (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
AU2013204147B2 (en) Treatment of TNFalpha related disorders
UA35854A (uk) Спосіб лікування приховано протікаючого силікотуберкульозу
UA32288A (uk) Спосіб лікування дегенеративних і запальних процесів
UA32108A (uk) Спосіб лікування хронічного тонзиліту
UA33359A (uk) Спосіб доступу до пухлин орбіти

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees